A simple blood test to choose the best treatment for each patient with depression.

Información del proyecto

RxMine

Identificador del acuerdo de subvención: 190160513

DOI

10.3030/190160513

Proyecto cerrado

Fecha de la firma de la CE 15 Septiembre 2022

Fecha de inicio 1 Junio 2022

Fecha de finalización 31 Mayo 2025

Financiado con arreglo a

• The European Innovation Council (EIC)

Coste total

€ 3 570 000,00

Aportación de la UE

€ 2 499 000,00

Coordinado por

GENETIKAPLUS LTD
Israel

Periodic Reporting for period 2 - RxMine (A simple blood test to choose the best treatment for each patient with depression.)

Período documentado: 2023-06-01 hasta 2025-05-31

Resumen del contexto y de los objetivos generales del proyecto

Major depressive disorder is the largest contributor to the reduction of health-related quality of life globally, with up to 14 years of life lost per patient. It affects 300M people globally and was the 2nd leading cause of disability in 2020, contributing to 917 accumulated years lost per 100k people and costing up to €170 billion per year to the EU. Nevertheless, 63% of people suffering from depression do not receive adequate treatment due to the heterogeneity of the disease, uniquely affecting each individual with highly varied responses to treatments. When choosing a drug for treatment, the physician must choose from over 70 different medications and combinations. As each drug takes 4-6 weeks to test the patient loses months to years of their lives to disability and suffering or risking suicide (15% commit suicide) in the process of searching for the right treatment. This trial-and-error process costs patients’ lives, physician's time and payer's and the government's major costs. Precision mental health treatment is urgently needed.
RXMine is the first decision support tool for personalized treatment of depression with a simple blood sample: it matches each patient with the right antidepressant saving patient lives, physician time and payer costs.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

GenetikaPlus has made significant scientific achievements in the last 12 months. These include:
• Structuring the first 3-pillared AI-based technology that a integrates, DNA, patient history and neurobiological models and predicts evidence-based drug recommendation. This technology could help doctors to identify new treatments for a variety of diseases, as it would allow them to analyze large amounts of data and identify patterns that would be difficult to spot with the naked eye.
• Expanding multiple clinical trials within the US and Israel that have boosted the company's research and activity. These trials have helped GenetikaPlus to gather valuable data about the effectiveness of its products and services, and they have also helped to raise awareness of the company's work.
• Developed the initial user interface for our physician platform, preparing us for market launch of our product.
• Securing CE-IVD, HIPAA and GDPR compliance levels. This was accompanied by advances in our QMS/GLP implementation and QA documentation. This means that GenetikaPlus's products and services meet the highest standards of quality and security and that they can be used in clinical settings.
• Expanding our platform to include analysis of more than 30 drugs. This has helped GenetikaPlus to build a comprehensive database of drug information, which can be used to help doctors to select the most appropriate treatment for their patients.
These are just a few of the scientific achievements that GenetikaPlus has made in the last 12 months. The company is committed to staying at the forefront of precise medicine technology, and it is confident that it will continue to make significant contributions to the field in the years to come.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

Overall, the potential impacts of RXMine are significant. The technology could revolutionize the way depression is treated, leading to better outcomes for patients and reducing the burden of the disease on society. Among the impacts:
• Reduce suffering: Currently, only 37% of patients respond to their first antidepressant medication. With RXMine, doctors more accurately predict which patients are likely to respond to a particular medication, leading to better outcomes for patients.
• Increased success rates of drug treatment: With RXMine, the success rate increases from 37% to 79% or higher, meaning that more patients would be able to find relief from their symptoms.
• Minimized adverse events by preventing prescription errors due to drug-drug interactions and contraindications: RXMine also helps to minimize adverse events by preventing prescription errors due to drug-drug interactions and contraindications.
• Improve success rates for physicians and reduce physician burnout: RXMine helps to improve success rates for physicians and reduce physician burnout. The technology would make it easier for physicians to find the right treatment for their patients, reducing the number of patients who do not respond to treatment and the amount of time physicians spend on trial-and-error.
• Assist providers and governments to reduce hospitalizations by making beds available for other patients: RXMine helps providers and governments to reduce hospitalizations, by making beds available for other patients.
• Save €5,000 per year per patient and up to €0.5Bn in total: The total economic impact of RXMine is significant. The company estimates that the technology could save €5,000 per year per patient, and up to €0.5Bn in total.

Genetika+ using AI and Brian-in-a-dish technology to find the best antidepressants for patients

Genetika+ presenting in 2023 American Psychiatric Association meeting (San Francisco).